DKFZ German Cancer Research Center

What DKFZ German Cancer Research Center does

Deutsches Krebsforschungszentrum (DKFZ), founded in 1964 and headquartered in Heidelberg, Germany, is the largest biomedical research institute in Germany and a member of the Helmholtz-Gemeinschaft and the Deutsche Zentren der Gesundheitsforschung. As a public law foundation (Stiftung des öffentlichen Rechts), DKFZ conducts fundamental and translational cancer research across five primary focus areas: cell and tumor biology, functional and structural genomics, epidemiology and cancer prevention, immunology and infection, and imaging and radiation oncology. The institute operates a national network of translational centers including the National Center for Tumor Diseases (NCT), the German Consortium for Translational Cancer Research (DKTK), the Hopp Children's Cancer Center Heidelberg (KiTZ), HI-TRON Mainz, the DKFZ-Hector Cancer Institute at University Medicine Mannheim, and the National Cancer Prevention Center (NCPC), serving academic and clinical cancer research communities across Germany and internationally.

DKFZ has built significant proprietary AI capability around cancer diagnostics, most notably the AI-based DNA methylation classifier (originally published in Nature in 2018) that now identifies 184 central nervous system tumor types after training on approximately 7,500 tumor samples, and has been used to analyze over 160,000 brain tumor samples globally through spin-off company Heidelberg Epignostix GmbH. In 2026, DKFZ and Heidelberg University Hospital announced Hetairos, an AI system that classifies over 100 CNS tumor molecular subtypes from standard histological slides, reducing diagnostic turnaround from approximately 12 days to 12 minutes and achieving 68% accuracy against 30% for experienced neuropathologists. Additional AI-driven projects include predicTCR (reducing therapeutic T-cell receptor identification time from approximately four months to less than two weeks), SpheroMouse (standardized tumor fragments), computational protein design for near-infrared fluorescent proteins, and the Digital Oncology cross-topic platform.

The institute is funded primarily through the German Federal Ministry of Education and Research (BMBF) and state governments as part of the Helmholtz framework, supplemented by European Research Council grants, collaborative research funding, and donations. DKFZ does not operate a commercial revenue model; instead, commercial value capture occurs through spin-off companies (Heidelberg Epignostix GmbH), academic publications in high-impact journals (Nature, JACS), and translational partnerships with university hospitals and pharmaceutical collaborators. The Krebsinformationsdienst public cancer information service provides free physician-staffed consultation daily, and the DKFZ Cancer Research Academy runs MSc, PhD, Postdoc, and Clinician Scientist training programs. The institute employs 1,001–5,000 staff and recently appointed Stefan Pfister as the new spokesperson of DKTK in June 2026.

Name

DKFZ German Cancer Research Center

Legal name

Deutsches Krebsforschungszentrum

Website

https://dkfz.de

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

DKFZ is Germany's largest biomedical research institute within the Helmholtz-Gemeinschaft, publicly funded to conduct translational cancer research spanning tumor biology, genomics, immunology, and imaging while developing AI-based diagnostic tools for academic and clinical cancer research communities.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industries

Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

Keywords

• Cancer research institute
• Biomedical research services
• Translational oncology research
• AI cancer diagnostics
• Immunotherapy development research

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Distribution channels2 records

Marketing channels6 records

Core offering

DKFZ (Deutsches Krebsforschungszentrum) is Germany's largest publicly funded biomedical research institute, conducting fundamental and translational cancer research across cell and tumor biology, functional and structural genomics, epidemiology, immunology, and imaging/radio-oncology. It develops AI-based diagnostic tools, including the DNA methylation classifier commercialized via its spin-off Heidelberg Epignostix GmbH, and provides a public cancer information service (Krebsinformationsdienst) alongside structured research training through the DKFZ Cancer Research Academy.

Product overview

DKFZ German Cancer Research Center operates as Germany's largest biomedical research institution (part of Helmholtz-Gemeinschaft and Deutsche Zentren der Gesundheitsforschung), developing AI-powered diagnostic tools and research platforms. The core offerings include the AI Methylation Classifier for brain tumor diagnosis (identifying 184 tumor types, commercialized via spin-off Heidelberg Epignostix GmbH) and the Hetairos AI diagnostic system for rapid brain tumor classification. Additional products include predicTCR (AI for T-cell receptor identification) and SpheroMouse (standardized tumor models). The center also maintains Digital Oncology as a cross-topic platform and provides the Krebsinformationsdienst public information service. Research priorities span cell/tumor biology, functional genomics, epidemiology, immunology, and imaging/radiooncology.

Differentiator

Problem solved

Functional benefit

Brands

• DKFZ Cancer Research Academy: Training and education programs including Major Cancer Biology (MSc), International PhD Program, International Postdoc Program, and Clinician Scientist Program
• Krebsinformationsdienst
• einblick
• Life-Science Lab

Products and services

• AI Methylation Classifier AI-based DNA methylation classifier that analyzes methylation patterns from tumor samples to classify central nervous system tumors into 184 distinct types, providing probability scores to help pathologists assess diagnostic reliability. The tool has been used to analyze over 160,000 brain tumor samples globally and is available to pathology labs via Heidelberg Epignostix GmbH.
• Hetairos Brain Tumor AI Diagnostic System AI system developed at DKFZ and Heidelberg University Hospital that classifies over 100 molecular subtypes of central nervous system tumors from standard histological slides. Trained on over 11,000 digitized images from 9,606 patients across eleven medical centers, it reduces diagnostic turnaround from approximately 12 days to 12 minutes and is positioned as a cost-effective adjunct to DNA methylation profiling for precision diagnostics.
• Krebsinformationsdienst (Cancer Information Service) Free cancer information service provided by DKFZ that offers daily consultation by physicians answering public questions about cancer via telephone (0800-4203040) and email, available daily from 8am to 8pm. Serves cancer patients, their families, and the general public seeking evidence-based cancer information.
• Digital Oncology Cross-topic research platform at DKFZ focused on digital oncology, integrating computational approaches, AI, and machine learning for cancer research and diagnostics. Provides infrastructure and collaboration framework for DKFZ researchers and partners working on data-driven cancer research.

Quantifiable outcome

• AI diagnostic system reduced brain tumor diagnosis turnaround from 12 days to 12 minutes with 68% accuracy vs 30% for specialist neuropathologists
• +2 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature5 records

Partnerships

16 partnerships are on record, tiered core and major.

• National Center for Tumor Diseases DresdencoreStrategic or Co-development Partner · 25 June 2026International research collaboration led by Professor Oliver Bruns at NCT Dresden, involving DKFZ scientists in development of novel fluorescent proteins for cancer detection. The proteins enable deeper tissue penetration and reduced autofluorescence for applications in cancer surgery and disease monitoring.
• University of WashingtonmajorStrategic or Co-development Partner · 25 June 2026Collaborating institution in international team developing novel near-infrared and short-wave infrared fluorescent proteins using computational protein design for cancer detection applications.
• Howard Hughes Medical InstitutemajorStrategic or Co-development Partner · 25 June 2026Collaborating institution in international research team developing novel fluorescent proteins for cancer detection, contributing to deeper tissue imaging capabilities.
• Heidelberg University HospitalcoreStrategic or Co-development Partner · 10 June 2026Collaborative development of Hetairos AI system for brain tumor diagnosis. The system classifies over 100 molecular subtypes of CNS tumors from histological slides, trained on images from 9,606 patients across eleven medical centers.
• Carl June Lab at University of PennsylvaniamajorStrategic or Co-development Partner · 19 April 2026Early access partner for 10x Genomics Atera spatial biology platform, generating data demonstrating whole-transcriptome spatial analysis capabilities with single-cell sensitivity at scale.
• University Hospital of TübingencoreStrategic or Co-development Partner · 4 February 2026Research collaboration identifying ATF6alpha as tumor driver for hepatocellular carcinoma. Study found that high ATF6alpha activity paradoxically makes tumors highly responsive to immunotherapy, suggesting potential as both therapeutic target and stratification marker.
• Sanford Burnham Prebys Medical Discovery InstitutemajorStrategic or Co-development Partner · 4 February 2026International research collaboration on liver cancer and immunotherapy response mechanisms, contributing to understanding of ATF6alpha's dual role as tumor driver and immunotherapy sensitivity marker.
• Hopp Children's Cancer Center Heidelberg (KiTZ)coreStrategic or Co-development Partner · 8 December 2025Joint development of AI-based methylation classifier for brain tumor diagnosis. Updated version identifies 184 tumor types (doubled from 91) after training on ~7,500 tumor samples. Tool originally published in Nature 2018 and made available as diagnostic product through spin-off company Heidelberg Epignostix GmbH.
• Heidelberg UniversitycoreStrategic or Co-development Partner · 8 December 2025Collaborating institution in development of AI-based methylation classifier for brain tumor diagnosis, now capable of identifying 184 tumor types.
• Heidelberg Epignostix GmbHcoreTechnology or Integration · 8 December 2025DKFZ spin-off company commercializing the AI-based methylation classifier as a diagnostic product. The tool has been used to analyze over 160,000 brain tumor samples globally.
• DKTK - Deutsches Konsortium für Translationale KrebsforschungcoreStrategic or Co-development PartnerNational translational cancer research consortium with multiple sites across Germany, part of DKFZ's translational centers network enabling clinical translation of research discoveries.
• NCT - Nationales Centrum für TumorerkrankungencoreStrategic or Co-development PartnerNational Center for Tumor Diseases Dresden as one of DKFZ's key translational centers bridging basic research and clinical application.
• HI-TRON Mainz - Helmholtz Institut für Translationale OnkologiecoreStrategic or Co-development PartnerHelmholtz Institute for Translational Oncology in Mainz, part of DKFZ's translational centers network for clinical translation of oncology research.
• NCPC - Nationales KrebspräventionszentrumcoreStrategic or Co-development PartnerNational Cancer Prevention Center focusing on strengthening tobacco and alcohol prevention, promoting healthy nutrition and exercise, and improving HPV vaccination access.
• Helmholtz-GemeinschaftcoreStrategic or Co-development PartnerDKFZ is the largest biomedical research institution in Germany and part of the Helmholtz Association, Germany's largest scientific organization, providing institutional framework and funding.
• Deutsche Zentren der GesundheitsforschungcoreStrategic or Co-development PartnerDKFZ is part of the German Centers for Health Research, a network of national research institutions focused on major disease areas including cancer.

Recent moves7 records

Expansion highlights8 records

Direct peers

• National Cancer Institute (NCI): The US federal government's principal agency for cancer research and training, and the world's largest funder of cancer research. NCI is the most direct peer to DKFZ in mission, scale, and structure as a government-funded national cancer research institute.
• Memorial Sloan Kettering Cancer Center: One of the world's oldest and largest private cancer centers, combining laboratory research with clinical care across all oncology subspecialties. Comparable to DKFZ's integrated research-and-clinical-translation model through its hospital and research programs.
• MD Anderson Cancer Center: The University of Texas MD Anderson Cancer Center is one of the largest cancer research and treatment centers globally. It mirrors DKFZ's model of integrating basic research with clinical translation at massive scale, with significant government and philanthropic funding.
• The Francis Crick Institute: A major biomedical research institute in London covering cancer alongside other diseases. Comparable to DKFZ as a publicly-funded national research powerhouse with a focus on interdisciplinary discovery science and translational research.
• Institut Curie: France's premier cancer research center combining a hospital with a research center, with a mission centered on cancer research, treatment, and teaching. Highly comparable to DKFZ as a European national cancer research institution with translational infrastructure.
• Institute of Cancer Research (ICR): A UK college of the University of London specializing in cancer research, with close ties to The Royal Marsden NHS Foundation Trust. Comparable to DKFZ in its focus on cancer-specific research and clinical translation, with strong commercial partnerships.
• Karolinska Institutet: Sweden's largest medical university and a leading European biomedical research institution with a strong focus on cancer research. Comparable to DKFZ as a publicly-funded European research university with significant oncology research programs and clinical integration.
• European Institute of Oncology (IEO): A leading European cancer research and treatment center founded in Milan, Italy. Comparable to DKFZ as a European institution combining cancer research with clinical translation and prevention programs.

Broad incumbents

• Broad Institute of MIT and Harvard: A leading genomics and biomedical research institute with strengths in computational biology, cancer genomics, and AI for biomedicine. Comparable to DKFZ on the AI-driven cancer diagnostics axis (e.g., methylation classifiers, large-scale data analysis) and translational research infrastructure.

Emerging players

• Heidelberg Epignostix GmbH: A DKFZ spin-off commercializing the AI-based DNA methylation classifier for brain tumor diagnosis globally. Comparable as the commercial vehicle for DKFZ's most mature AI diagnostic technology and a model for future DKFZ spin-offs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/dkfz
• Instagraminstagram.com/dkfz
• LinkedInlinkedin.com/company/dkfz---german-cancer-research-center

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DKFZ German Cancer Research Center